Aniracetam

DB04599

small molecule experimental

Deskripsi

Compound with anti-depressive properties used as a mental performance enhancer.

Struktur Molekul 2D

Berat 219.2365
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 1-2.5 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

677 Data
Buprenorphine Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Aniracetam.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Aniracetam.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Aniracetam.
Hydrocodone Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Aniracetam.
Magnesium sulfate The therapeutic efficacy of Aniracetam can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Aniracetam may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Aniracetam.
Mirtazapine Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Aniracetam.
Orphenadrine Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Aniracetam.
Pramipexole Aniracetam may increase the sedative activities of Pramipexole.
Ropinirole Aniracetam may increase the sedative activities of Ropinirole.
Rotigotine Aniracetam may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Aniracetam.
Sodium oxybate Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Aniracetam.
Thalidomide Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Aniracetam.
Dicoumarol The risk or severity of adverse effects can be increased when Aniracetam is combined with Dicoumarol.
Phenindione The risk or severity of adverse effects can be increased when Aniracetam is combined with Phenindione.
Warfarin The risk or severity of adverse effects can be increased when Aniracetam is combined with Warfarin.
Phenprocoumon The risk or severity of adverse effects can be increased when Aniracetam is combined with Phenprocoumon.
Acenocoumarol The risk or severity of adverse effects can be increased when Aniracetam is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of adverse effects can be increased when Aniracetam is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of adverse effects can be increased when Aniracetam is combined with Coumarin.
(R)-warfarin The risk or severity of adverse effects can be increased when Aniracetam is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of adverse effects can be increased when Aniracetam is combined with Ethyl biscoumacetate.
Fluindione The risk or severity of adverse effects can be increased when Aniracetam is combined with Fluindione.
Clorindione The risk or severity of adverse effects can be increased when Aniracetam is combined with Clorindione.
Diphenadione The risk or severity of adverse effects can be increased when Aniracetam is combined with Diphenadione.
Tioclomarol The risk or severity of adverse effects can be increased when Aniracetam is combined with Tioclomarol.
(S)-Warfarin The risk or severity of adverse effects can be increased when Aniracetam is combined with (S)-Warfarin.
Ethanol Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Aniracetam.
Zimelidine The risk or severity of adverse effects can be increased when Aniracetam is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Aniracetam is combined with Dapoxetine.
Seproxetine The risk or severity of adverse effects can be increased when Aniracetam is combined with Seproxetine.
Fluvoxamine The risk or severity of adverse effects can be increased when Aniracetam is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Aniracetam is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Aniracetam is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Aniracetam is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Aniracetam is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Aniracetam is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Aniracetam is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Aniracetam is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Aniracetam is combined with Escitalopram.
Milnacipran The risk or severity of adverse effects can be increased when Aniracetam is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Aniracetam is combined with Desvenlafaxine.
Levomilnacipran The risk or severity of adverse effects can be increased when Aniracetam is combined with Levomilnacipran.
Indalpine The risk or severity of adverse effects can be increased when Aniracetam is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Aniracetam is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Aniracetam is combined with Alaproclate.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Aniracetam.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Aniracetam.
Zopiclone The risk or severity of adverse effects can be increased when Aniracetam is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Aniracetam.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Aniracetam.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Aniracetam.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Aniracetam.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Aniracetam.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Aniracetam.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Aniracetam.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Aniracetam.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Aniracetam.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Aniracetam.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Aniracetam.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Aniracetam.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Aniracetam.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Aniracetam.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Aniracetam.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Aniracetam.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Aniracetam.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Aniracetam.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Aniracetam.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Aniracetam.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Aniracetam.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Aniracetam.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Aniracetam.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Aniracetam.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Aniracetam.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Aniracetam.
Thiethylperazine The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Aniracetam.
Palonosetron The risk or severity of CNS depression can be increased when Palonosetron is combined with Aniracetam.
Dexbrompheniramine The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Aniracetam.
Metocurine iodide The risk or severity of CNS depression can be increased when Metocurine iodide is combined with Aniracetam.
Secobarbital The risk or severity of CNS depression can be increased when Secobarbital is combined with Aniracetam.
Methocarbamol The risk or severity of CNS depression can be increased when Methocarbamol is combined with Aniracetam.
Triprolidine The risk or severity of CNS depression can be increased when Triprolidine is combined with Aniracetam.
Meperidine The risk or severity of CNS depression can be increased when Meperidine is combined with Aniracetam.
Metharbital The risk or severity of CNS depression can be increased when Metharbital is combined with Aniracetam.
Quinine The risk or severity of CNS depression can be increased when Quinine is combined with Aniracetam.
Methohexital The risk or severity of CNS depression can be increased when Methohexital is combined with Aniracetam.

Target Protein

D(2) dopamine receptor DRD2
5-hydroxytryptamine receptor 2A HTR2A
Glutamate receptor 2 GRIA2
Glutamate receptor 3 GRIA3

Referensi & Sumber

Artikel (PubMed)
  • PMID: 11412837
    Nakamura K, Kurasawa M: Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
  • PMID: 12869631
    Lawrence JJ, Brenowitz S, Trussell LO: The mechanism of action of aniracetam at synaptic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors: indirect and direct effects on desensitization. Mol Pharmacol. 2003 Aug;64(2):269-78.

Contoh Produk & Brand

Produk: 0 • International brands: 2
International Brands
  • Draganon
  • Sarpul

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul